Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Additional Indication of Xeloda, Elplat to Be Reported to PAFSC’s 2nd Committee on Oct. 29
October 16, 2015
- High Unmet Medical Need for Lenalidomide: Council on Unapproved Drugs
October 16, 2015
- MHLW Council on Unapproved Drugs to Review Appropriateness of Humanitarian Trials, Notification Due Out November
October 15, 2015
- Chuikyo Subcommittee Roughly OKs Sakigake Pricing Premium, Yet No Agreement on Rate Raise
October 15, 2015
- Chuikyo Payer Reps Wary of Revising Foreign Price Adjustment Rule for Govt-Requested Drugs
October 15, 2015
- Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
- MOF Pitches Reimbursement Rate Cuts for OTC-Switched Ethical Drugs, Submission of Related Bills Eyed in 2017
October 13, 2015
- Takeuchi, Tokashiki Picked as Senior Vice Health Minister
October 13, 2015
- TPP Will Have No Impact on Japan’s Universal Care Scheme: Negotiator
October 9, 2015
- FY2013 Medical Expenditure Tops 40 Trillion Yen to Hit New High
October 9, 2015
- Chuikyo Payer and Doctor Reps Exchange Barbs on Spike in Generic Brand-Specified Scripts
October 8, 2015
- Abe’s New Cabinet Retains Shiozaki, Pro-Generics Kono Named as Administrative Reform Minister
October 8, 2015
- 8 Year Biologic Data Protection in TPP Won’t Affect Japan: MHLW Official
October 7, 2015
- MHLW Looks to Establish Panel to Draft Guidelines for English-Language Inserts
October 6, 2015
- Humanitarian Trial Data Will Be Supplementary Reference to Confirmatory Studies: Govt
October 5, 2015
- Chuikyo Approves Draft Framework for Patient-Initiated Mixed Care; Will Establish Evaluation Council by Next Spring
October 2, 2015
- PAFSC Committee Approves Resumed Shipments of Kaketsuken’s Venilon due to Potential Shortage of Substitutes
October 2, 2015
- Drug Pricing Organization to Price JCR’s Cell Therapy Temcell
October 1, 2015
- JPWA Calls for Fair Sharing of Distribution Costs for Premium-Granted Products
October 1, 2015
- Chuikyo Debate Heats Up on Number of Generic Brands, Makers; JGA Floats New 3 Price-Band Rule
October 1, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…